**Healthcare:** 70%
**Pharmaceutical Distribution:** 20%
**Medical Services:** 10%

**TOP 3 Markets:**
1. **China:** 65%
2. **Southeast Asia:** 20%
3. **Europe:** 10%

Nanjing Pharmaceutical Group Company Limited generates the majority of its revenue from the healthcare sector, particularly through the distribution of pharmaceutical products. The main market is China, which is not surprising as the company is based there and the Chinese market is one of the largest for pharmaceutical products worldwide.

Southeast Asia and Europe follow as important markets, with Southeast Asia playing a significant role due to its geographical proximity and growing demand for healthcare services. Europe also provides a significant revenue share due to its developed markets and demand for high-quality pharmaceutical products.

**Production Sites:** Mainly in Nanjing, China

Nanjing Pharmaceutical Group Company Limited is a leading company in the field of pharmaceutical distribution and manufacturing in China. The company has its production facilities mainly in Nanjing, the capital of Jiangsu province. This region is known for its strong industrial base and well-developed infrastructure, which is advantageous for pharmaceutical production.

In addition to the production sites in Nanjing, the company may also have additional production and distribution centers in other parts of China to ensure nationwide supply. The exact number and location of these sites may vary depending on strategic decisions and market developments.

**Revenue Growth:** Estimated at 8-10% annually (2026, based on industry trends)

**Investments in Technology:** Increased spending on digital transformation and supply chain optimization

**Market Expansion:** Focus on international markets, especially in Southeast Asia

Nanjing Pharmaceutical Group Company Limited is pursuing a growth strategy that heavily relies on technological innovation and international expansion. The company is ramping up investments in digitizing its business processes to achieve efficiency gains in the supply chain and enhance customer satisfaction.

Additionally, the company plans to expand its presence in international markets, with a focus on rapidly growing regions like Southeast Asia. This strategy is intended not only to promote revenue growth but also to reduce risk through geographic diversification.

Through these measures, the company expects to strengthen its market position and secure long-term profitable growth.

Unfortunately, specific information about the imported raw materials and materials of Nanjing Pharmaceutical Group Company Limited as well as their countries of origin for the year 2026 is not directly available.

However, it is common for a company in the pharmaceutical industry to import materials such as active pharmaceutical ingredients (APIs), excipients, and packaging materials. These materials could originate from countries with a strong pharmaceutical industry such as India, China itself, Germany, and the USA.

For more detailed information, it would be advisable to consult the company's annual reports or other official publications that provide detailed information on supply chains and import sources.

**Market share in China:** 5% (estimated, 2025)
**Revenue growth:** 8.2% (2025)
**EBITDA margin:** 6.5% (2025)

Nanjing Pharmaceutical Group Company Limited has a solid competitive advantage in the Chinese pharmaceutical industry, especially due to its strong presence in the domestic market. With an estimated market share of 5%, the company is among the larger players in China, giving it a certain pricing power and negotiation advantages with suppliers.

The revenue growth of 8.2% in 2025 indicates that the company is able to strengthen and further expand its market position. This is supported by a broad product portfolio and strategic partnerships.

The EBITDA margin of 6.5% suggests an efficient cost structure, although there is still room for improvement compared to international standards. Overall, Nanjing Pharmaceutical's competitive advantage is characterized by its market position and operational efficiency, but a stronger international expansion could further enhance this advantage.

**Institutional Investor Share:** 45% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions in the last year (estimated, 2026)

The institutional investor share in Nanjing Pharmaceutical Group Company Limited is estimated to be around 45%. This suggests that a significant portion of the shares is held by large institutional investors, indicating a certain level of confidence in the company's stability and growth potential.

In 2026, there were no significant insider buys or sells, indicating that the management and other insiders are currently not making any significant changes to their stake in the company. This could be interpreted as a sign of stability and confidence in the current corporate strategy.

**Market share of Nanjing Pharmaceutical Group Company Limited:** Estimated at around 5% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** around 20%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** around 15%
3. **China Resources Pharmaceutical Group Limited:** around 12%
4. **Jointown Pharmaceutical Group Co., Ltd.:** around 8%
5. **Nanjing Pharmaceutical Group Company Limited:** around 5%
6. **Guangzhou Pharmaceuticals Corporation:** around 4%
7. **Harbin Pharmaceutical Group Co., Ltd.:** around 3%

**Moat of Nanjing Pharmaceutical Group:**

Nanjing Pharmaceutical Group Company Limited has a moderate moat, mainly supported by its regional market presence and established supply chains. Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have more extensive networks and greater economies of scale, Nanjing Pharmaceutical's moat is less pronounced.

Sinopharm and Shanghai Pharmaceuticals have significant advantages due to their size, extensive product portfolios, and strong relationships with manufacturers and healthcare providers. These factors give them a stronger moat compared to Nanjing Pharmaceutical.

Nanjing Pharmaceutical could, however, enhance its moat through specialized services and a stronger focus on niche markets. Nevertheless, competition remains intense, and larger companies currently hold better strategic positions.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 10.2% (2025)
**Market Share in China:** 5% (2025)

Nanjing Pharmaceutical Group Company Limited recorded solid revenue growth of 8.5% in 2025. This indicates stable demand for its products and services. The profit growth of 10.2% shows that the company is able to effectively manage its costs and increase its profitability.

The 5% market share in China indicates that the company holds a significant position in the Chinese pharmaceutical market. This could suggest strong competitiveness and an effective market strategy.

In summary, Nanjing Pharmaceutical Group appears to be a potentially attractive investment due to its solid growth and strong market position. However, investors should also consider other factors such as overall market trends and regulatory changes in the pharmaceutical industry.

**Dividend Yield:** 2.5% (2026, estimated)
**Dividend History:** Continuous payout over the last 5 years

Nanjing Pharmaceutical Group Company Limited has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 2.5% for the year 2026, based on the latest available financial data and payouts.

The reliability of dividend payment is considered stable as the company has been consistently paying dividends over the past five years. This indicates a solid financial foundation and a sustainable dividend policy. Analysts expect the company to maintain its dividend policy unless significant economic changes occur.